Selection of blockbuster announcements

1. China Resources Medical profit warning: the profit attributable to the owner of the parent company is expected to decline by about 65% in 2022 compared with the same period last year.

$CR MEDICAL (01515.HK)$Profits attributable to parent owners are expected to fall by about 65% in 2022 compared with the same period last year. Mainly due to the previous acquisition of Huaiyin Hospital operating losses and impairment totaling about 220 million yuan, as well as about 160 million yuan exchange loss.

2. Ninety-nine profit alarms:The profit attributable to the company's equity shareholders is not less than 47 million yuan, down about 86.2% from the same period last year.

$Jiumaojiu International Holdings Limited (09922.HK)$According to the announcement, the group is expected to achieve revenue of about 4.006 billion yuan in 2022, down about 4.2% from the same period last year; the profit attributable to the company's equity shareholders is not less than 47 million yuan, down about 86.2% from the same period last year.

3. China Mobile Limited released customer data for January: as of January, the number of customers of 5G package reached 622.47 million.

$CHINA MOBILE (00941.HK)$Release of January 2023 operating data, mobile business, the total number of customers reached 975.509 million, this month a net increase of 503000 customers, 5G package customers totaled 622.474 million. In terms of cable broadband service, the total number of customers reached 274.697 million, with a net increase of 2.529 million this month.

4. China Unicom: the total number of 5G package users reached about 216 million in January, and the problem resolution rate of smart customer service customers reached 98.3%.

$CHINA UNICOM (00762.HK)$According to the announcement, in January 2023, the total number of "Big connection" users reached about 873 million, 5G package users reached about 216 million, and Internet of things terminal connections reached about 395 million. The number of customers of virtual private network service in 5G industry is 4012. In that month, the problem resolution rate of smart customer service reached 98.3%, and that month, intelligent customer service accounted for 81%. A total of 88 patents have been granted this year.

5. China Telecom Corporation net increased 5.03 million users of 5G package in January.

$CHINA TELECOM (00728.HK)$According to the operating data for January 2023, the number of mobile users in that month was 392.31 million, with a net increase of 1.13 million in that month. Among them, the number of 5G package users reached 272.99 million, with a net increase of 5.03 million in the same month.

6. Junshi biology: the phase III clinical study of triplizumab combined with chemotherapy in patients with advanced triple negative breast cancer reached the main end point.

$JUNSHI BIO (01877.HK)$Recently, the company's product triplizumab combined with paclitaxel for injection (albumin-bound) has been used in a randomized, double-blind, placebo-controlled, multicenter III phase clinical trial for patients with newly diagnosed stage IV or recurrent and metastatic triple negative breast cancer, and the Independent data Monitoring Committee (IDMC) has determined that the main end points of the study have reached the predetermined efficacy threshold. The company will communicate with the regulatory authorities to submit the application for listing of the new indication in the near future.

7. Golly Pharmaceuticals-B: release of positive phase I clinical data of broad-spectrum antiviral dual prodrug ASC10

$ASCLETIS-B (01672.HK)$According to the announcement, Golly has released phase I clinical trial data of the broad-spectrum antiviral dual prodrug ASC10 at the 2023 retrovirus and opportunistic infections Conference (CROI) in Seattle, USA. Preclinical studies have shown that ASC10-A has broad-spectrum antiviral activity and has strong antiviral activity against novel coronavirus, monkeypox virus and respiratory syncytial virus (RSV).

Financial data

Interim net profit of Guohao Group (00053) increased by 106% to HK $1.272 billion interim interest of HK $0.50.

Meitu (01357) Yingxi: expected to turn a loss into a profit of about 85 million to 130 million yuan

Huitongda Network (09878) is expected to turn a loss into a profit in 2022: the profit attributable to the company's equity holders is not less than 285 million yuan.

China Resources Medical (01515) earnings Police: annual profit is expected to decline by about 65%.

The profit attributable to the equity shareholders of the company is estimated to be not less than 47 million yuan in 09922.

Merger and acquisition and sale

Green Power Environmental Protection (01330) plans to acquire shares in several companies to expand the scale of domestic waste incineration power generation business.

China Xinlianxin Chemical Fertilizer (01866) plans to acquire 100% equity of Xinxiang Shenzhou anticorrosion installation with 8.8851 million yuan.

Investment and operation

Junshi Bio (01877): application for marketing license of triplet monoclonal antibody is accepted by UK Drug and Health products Administration

Sino Biopharmaceutical (01177): the therapeutic drug "Lima prost tablet" in the field of analgesia and microcirculation has been approved to go on the market.

China Everbright Water (01857) signed the PPP project contract for the third sewage treatment plant and its supporting pipe network project in Shenxian County, Liaocheng City, Shandong Province.

Shanghai Pharmaceutical (02607): application for listing license of X842 project is accepted

Junshi Bio (01877): application for listing license of triplet monoclonal antibody accepted by UK Drug and Health products Administration

Repurchase cancellation

Great Wall Motor (02333) spent HK $236 million to buy back 21.048 million shares on February 20.

Equity incentive

Dream World (01119) Grant 700000 restricted shares

Edit / ruby